The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Scientists have discovered that semaglutide, the active ingredient in drugs like Ozempic and Wegovy, offers a new benefit for ...

Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH treatment plan.

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

In patients with coronary artery disease (CAD) and obesity, tirzepatide was associated with lower mortality and reduced ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

For an older person with type 2 diabetes, especially someone already at risk of frailty, a GLP 1 or SGLT 2 medicine, where ...

A large US-based study has found that people with type 2 diabetes taking GLP-1 drugs such as Ozempic may be slightly less ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

If you have MASH, GLP-1 medications may help treat the condition. Set yourself up for success with expert advice on diet, exercise, dose scheduling, and more.